SLC5A2 and type 2 diabetes mellitus: Sodium–glucose co-transporter 2 (SGLT2) inhibitors prevent the reabsorption of glucose in the kidney and increase urinary excretion of glucose,11 and several members of this class have been approved for the treatment of T2DM in human beings.